New agent causes small cell lung tumors to shrink in pre-clinical testing
Small cell lung cancer – a disease for which no new drugs have been approved for many years – has shown itself vulnerable to an agent that disables part of tumor cells’ basic survival machinery, researchers at Dana-Farber Cancer Institute and the Massachusetts Institute of Technology reported.
In a study published today in the journal Cancer Cell, the investigators found that the agent THZ1 caused human-like small cell lung tumors in mice to shrink significantly, with no apparent side effects. The compound is now being developed into a drug for testing in human patients in clinical trials.
“Small cell lung cancer is a disease for which new treatments are desperately needed,” said Kwok-Kin Wong, MD, PhD, co-senior author of the study and medical oncologist at Dana-Farber. “Patients generally respond well to initial chemotherapy, but the disease almost always returns. Less than 5 percent of patients are alive five years after being diagnosed with the disease.”
Small cell lung cancer (SCLC) accounts for 10-15 percent of lung cancer cases and is the most aggressive form of lung malignancy. Although small cell lung tumors have many mutated genes, none of these is known to be a “driver” – a gene that actually spurs tumor growth – and none makes a good target for drug therapy. As a result, researchers have sought other strategies for attacking the disease.
Dana-Farber researchers began with mice that had small cell lung tumors engineered to resemble those in humans. Extracting tumor tissue from the animals, the researchers screened more than 1,000 small molecule blockers in the cell samples to see if any halted tumor cell growth. The one that worked best was THZ1, a compound designed by chemical biologists at Dana-Farber that inhibits a cell protein known as cyclin-dependent kinase 7 (CDK7).
CDK7 is known to play a key role in gene transcription, the process by which genetic information stored in DNA is copied onto RNA. Inhibiting CDK7, therefore, strikes at the basic machinery of transcription. But since transcription occurs in all cells, researchers explored why THZ1 is effective at killing SCLC cells but left healthy cells unharmed.
The answer lies in sections of genetic material known as super-enhancers, long stretches of DNA that exert extensive control over transcription in tumor cells. The researchers found that THZ1 suppresses certain genes within these regions that SCLC cells depend on to survive and grow. Because normal cells do not rely on super-enhancers to the same degree, they are largely unaffected by THZ1.
“We found that SCLC cells are ‘addicted’ to transcription in a way that normal cells are not,” Wong observed. “They appear to depend on short-lived transcripts – briefly existing RNA copies – that aren’t as critical to normal cells. This explains why normal cells can tolerate a drug that targets the basic transcription mechanism while SCLC cells cannot.
The key to the effectiveness of drugs derived from THZ1 will be finding the correct “therapeutic window” for patients – the dose and administration schedule that produces the greatest therapeutic effect while producing the fewest side effects, Wong continued. Clinical trials will help determine that window.
The study was funded by grants from the National Institutes of Health; the Thoracic Foundation; the Susan Spooner Foundation; The Bridge Project, a collaboration between Dana-Farber/Harvard Cancer Center (DF/HCC) and the Koch Institute for Integrative Cancer Research at MIT; and a fellowship from the Danish Cancer Society.
The lead author of the study is Camilla Christensen, PhD, of Dana-Farber. Joining Wong as co-senior authors are Nathanael Gray, PhD, of Dana-Farber, and Richard Young, PhD, of the Whitehead Institute for Biomedical Research at the Massachusetts Institute of Technology. Co-authors are Tinghu Zhang, PhD, Grit Herter-Sprie, MD, Esra Akbay, PhD, Abigail Altabef, Jianming Zhang, Marzia Capelletti, Jakob Reibel, Jillian Cavanaugh, Peng Gao, Yan Liu, PhD, Amir Aref, PhD, David Barbie, MD, and James Bradner, MD, of Dana-Farber; Edmond Chipumuro, PhD, and Rani George, MD, PhD, of Dana-Farber and Boston Children’s Hospital; Nicholas Kwiatkowski, PhD, and Brian Abraham, PhD, of the Whitehead Institute; Julian Carretero of the Universitat de Valencia, Valencia, Spain; Fatima Al-shahrour, PhD, of the Spanish National Cancer Research Center, Madrid, Spain; Takeshi Shimamura, PhD, of Loyola University; and Signe Michaelsen, PhD, and Hans Poulsen, MD, of Copenhagen University Hospital, Copenhagen, Denmark.